New “webmarking” system for registered designs

Innovative designs are big business. A recent report for NESTA [1] estimated that 10% of investment in intangible assets relates to design, and this is reflected in the increasing number of new designs being filed – over 5000 [2] just in the UK last year and close to a staggering...

Read more

Imitation is the sincerest form of flattery! Isn’t it?

Imitation noun “a copy or reproduction of a genuine article; counterfeit” Flattery noun “excessive and insincere praise, given especially to further one’s own interests” Imitation goods cost the fashion industry billions each year, diluting and damaging the reputation of even the most well-known brands whilst lining the pockets of the counterfeiters....

Read more

The Gold Standard for Amendments – Have the EPO Guidelines Got it Wrong?

The recent EPO Technical Board of Appeal decision T1363/12 has shed some light on how the test for added subject matter should be applied. In doing so, it has poured scorn on the guidance set out in the new Guidelines for Examination. Background Amendments to European patent specifications, whether made...

Read more

Are Granted Claims in the Clear?

Just a few months ago we reported the referral of a number of questions to the EPO Enlarged Board of Appeal (designated G3/14). Given the importance of the answers to those questions, the Enlarged Board has returned a speedy, albeit ambiguous answer. The questions referred to the Enlarged Board concerned...

Read more

Name That Drug

The role of the European Medicines Agency (EMA) as a regulator is to protect and promote public and animal health by evaluating and supervising medication for both human and veterinary use. The EMA was created to harmonise the working practices of the various EU member state territories. It also reduces...

Read more